C Schnell Selected Research

Tyrosine (L-Tyrosine)

4/2000

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

C Schnell Research Topics

Disease

3	Nemaline Myopathies (Nemaline Myopathy) 02/2003 - 06/2000
3	Neoplasms (Cancer) 12/2001 - 04/2000
1	Atrophy 02/2003
1	Hypertrophy 02/2001
1	Neoplasm Metastasis (Metastasis) 09/2000

Drug/Important Bio-Agent (IBA)

3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2001 - 04/2000
2	Actins (F Actin)IBA 02/2003 - 06/2000
2	TropomyosinIBA 02/2003 - 02/2001
1	GlycogenIBA 02/2003
1	Proteins (Proteins, Gene)FDA Link 02/2003
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 12/2001
1	EndostatinsIBA 09/2000
1	Protein SIBA 09/2000
1	Phosphotransferases (Kinase)IBA 04/2000
1	vatalanib (PTK787)IBA 04/2000
1	Tyrosine (L-Tyrosine)FDA Link 04/2000
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 04/2000
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 04/2000

Therapy/Procedure

1	Intravenous Administration 09/2000
1	Oral Administration 04/2000